Trimethadione

{{Short description|Anticonvulsant}}

{{about|the drug Tridione|the content management software Tridion|SDL plc}}

{{Drugbox

| Watchedfields = changed

| verifiedrevid = 470615072

| IUPAC_name = 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione

| image = Trimethadione.svg

| width = 130

| tradename = Tridione

| Drugs.com = {{drugs.com|CONS|trimethadione}}

| pregnancy_category = X

| legal_status = Rx-only

| routes_of_administration = By mouth

| bioavailability = High

| metabolism = Demethylated to dimethadione

| elimination_half-life = 12–24 hours (trimethadione)
6–13 days (dimethadione)

| excretion = Renal

| IUPHAR_ligand = 7316

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 127-48-0

| ATC_prefix = N03

| ATC_suffix = AC02

| PubChem = 5576

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank = DB00347

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 5374

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = R7GV3H6FQ4

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D00392

| ChEMBL_Ref = {{ebicite|correct|EBI}}

| ChEMBL = 695

| ChEBI = 9727

| C=6 | H=9 | N=1 | O=3

| smiles = O=C1N(C(=O)OC1(C)C)C

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChI = 1S/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = IRYJRGCIQBGHIV-UHFFFAOYSA-N

}}

Trimethadione (Tridione) is an oxazolidinedione anticonvulsant. It is most commonly used to treat epileptic conditions that are resistant to other treatments.

It is primarily effective in treating absence seizures, but can also be used in refractory temporal lobe epilepsy. It is usually administered 3 or 4 times daily, with the total daily dose ranging from 900 mg to 2.4 g. Treatment is most effective when the concentration of its active metabolite, dimethadione, is above 700 μg/mL. Severe adverse reactions are possible, including Steven Johnson syndrome, nephrotoxicity, hepatitis, aplastic anemia, neutropenia, or agranulocytosis. More common adverse effects include drowsiness, hemeralopia, and hiccups.{{cite book |page=466 |title=AMA Drug Evaluations |edition=3rd |date=1977 |publisher=Pub. Sciences Group |location=Littleton, Mass. |author=American Medical Association Dept of Drugs |isbn=978-0-88416-175-2 |oclc=1024170745}}{{cite book |isbn=978-0-39754-230-7|title=Pharmacology and Drug Therapy in Nursing| vauthors = Rodman MJ, Smith DW |year=1979|page=259|publisher=Lippincott }}